Cardiovascular-derived Circulating Cell-Free DNA Fragments are Associated with Frailty and Increased Cardiovascular Events in Older Adults.

Abstract

Increased cellular damage in aging tissues releases circulating cell-free genomic DNA (ccf-gDNA) into the bloodstream, and these fragments are associated with a higher risk of frailty and dementia. We hypothesized that identifying the tissue of origin for ccf-gDNA using methylation signatures can distinguish subgroups of participants with distinct clinical outcomes, biological aging rates, and energy use. Serum ccf-gDNA from 181 participants in the Religious Orders Study or Rush Memory and Aging Project (ROS-MAP) was assessed for DNA methylation at one timepoint using the Illumina Methylation EPIC array. Clinical outcomes six years after ccf-gDNA measurement were determined for the following: frailty, cognitive test scores, and cardiovascular disease. Hierarchical clustering identified major clusters based on the predominance of ccf-gDNA source: Cardiovascular, Erythrocyte Progenitor, and Immune Cell. Participants with cardiovascular-enriched ccf-gDNA (CV ccf-gDNA) had higher rates of myocardial infarction (39%) at the last study visit compared to other subgroups (immune ccf-gDNA 21%, erythrocyte ccf-gDNA 23%), and similar findings were observed for congestive heart disease and stroke. There were no significant associations between cognitive test scores and ccf-gDNA subgroups. Individuals with CV ccf-gDNA demonstrated 3.1 times higher odds of being frail compared to the other groups and showed increased epigenetic age acceleration for the fragments compared to the other subgroups, indicating that this group was enriched with ccf-gDNA originating from older cells. The CV ccf-gDNA subgroup exhibited dysregulation of glycine and serine metabolism and pathways integral to cardiovascular health, endothelial function, and inflammation. We demonstrate that ccf-gDNA methylation patterns can detect high-turnover tissues and identify older adults at higher risk of frailty and cardiovascular disease.